JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

Search

MacroGenics Inc

Chiusa

SettoreSettore sanitario

1.59 -5.92

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.58

Massimo

1.6800000000000002

Metriche Chiave

By Trading Economics

Entrata

4.8M

-36M

Vendite

9M

22M

Margine di Profitto

-162.992

Dipendenti

341

EBITDA

5.7M

-33M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+102.7% upside

Dividendi

By Dow Jones

Utili prossimi

4 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

28M

121M

Apertura precedente

7.51

Chiusura precedente

1.59

Notizie sul Sentiment di mercato

By Acuity

67%

33%

336 / 373 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

MacroGenics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 ott 2025, 23:28 UTC

Azioni calde

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

29 ott 2025, 23:07 UTC

Utili

Prudential PLC 3Q New Business Profit Up 13%

30 ott 2025, 00:00 UTC

Utili

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

30 ott 2025, 00:00 UTC

Utili

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

30 ott 2025, 00:00 UTC

Utili

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

29 ott 2025, 23:46 UTC

Discorsi di Mercato

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

29 ott 2025, 23:40 UTC

Utili

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

29 ott 2025, 23:38 UTC

Discorsi di Mercato

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

29 ott 2025, 23:25 UTC

Utili

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

29 ott 2025, 22:51 UTC

Utili

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

29 ott 2025, 22:45 UTC

Utili

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

29 ott 2025, 22:41 UTC

Utili

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

29 ott 2025, 22:41 UTC

Utili

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

29 ott 2025, 22:09 UTC

Utili

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

29 ott 2025, 22:08 UTC

Discorsi di Mercato
Utili

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

29 ott 2025, 21:58 UTC

Utili

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

29 ott 2025, 21:58 UTC

Utili

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

29 ott 2025, 21:57 UTC

Utili

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

29 ott 2025, 21:54 UTC

Utili

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

29 ott 2025, 21:46 UTC

Utili

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

29 ott 2025, 21:43 UTC

Utili

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

29 ott 2025, 21:43 UTC

Utili

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

29 ott 2025, 21:42 UTC

Utili

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

29 ott 2025, 21:42 UTC

Utili

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

29 ott 2025, 21:41 UTC

Utili

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

29 ott 2025, 21:41 UTC

Utili

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

29 ott 2025, 21:41 UTC

Utili

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

29 ott 2025, 21:41 UTC

Utili

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

29 ott 2025, 21:40 UTC

Utili

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

29 ott 2025, 21:39 UTC

Utili

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Confronto tra pari

Modifica del prezzo

MacroGenics Inc Previsione

Obiettivo di Prezzo

By TipRanks

102.7% in crescita

Previsioni per 12 mesi

Media 3.75 USD  102.7%

Alto 5 USD

Basso 3 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per MacroGenics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

6 ratings

3

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.47 / 1.64Supporto e resistenza

A breve termine

Neutral Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

336 / 373 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
help-icon Live chat